This is a review of the current state of molecular profiling in gastrointestinal (GI) cancers and what to expect from this evolving field in the future. Individualized medicine is moving from broad panel testing of numerous genes or gene products in tumor biopsy samples, identifying biomarkers of prognosis and treatment response, to relatively noninvasive liquid biopsy assays, building on what we have learned in our tumor analysis and growing into its own evolving predictive and prognostic subspecialty. Hence, the field of GI precision oncology is exploding, and this review endeavors to summarize where we are now in preparation for the journey ahead.
Keywords: Biomarker; CTC; Colorectal cancer; Gastroesophageal cancer; Gastrointestinal, GI; Hepatobiliary cancer; Liquid biopsy; Molecular profiling; Next-generation sequencing, NGS; Pancreatic cancer; ctDNA.
© 2022. The Author(s).